Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib + Pegylated Interferon in Polycythemia Vera
NCT07445893Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of jaktinib in polycythemia vera (PV). Primary endpoint: Hematologic remission rate at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
jaktinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07445893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445893.